- Primary endpoint, change in DUX4-driven gene expression which was included as an experimental biomarker, was not met
- Losmapimod showed statistically significant* (p
Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
Watch Fulcrum Therapeutics' latest callFulcrum Therapeutics (NASDAQ:FULC) Q1 2026 Earnings Call · Replay · Apr 27Read the transcript of Fulcrum Therapeutics (NASDAQ:FULC) Q1 2026 Earnings CallFulcrum Therapeutics, Inc. on 6ix
Story so far
- Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
- Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
- Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
Earlier from Fulcrum Therapeutics
- Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)
- Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
- Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
- Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
- Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer
Later from Fulcrum Therapeutics
- Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8: 00 a.m. ET
- Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
- Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
- Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
- Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Follow Fulcrum Therapeutics into a list and get an email when it puts out news.
Follow Fulcrum Therapeutics